COMMUNIQUÉS West-GlobeNewswire

BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
02/11/2026
CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Compass Therapeutics to Participate in Upcoming November Investor Events
02/11/2026
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple [...]
Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference
02/11/2026
CINCINNATI, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2026 Global Healthcare Conference on Monday, November 9, 2026, at approximately [...]
Integrity Urgent Care Clinic Opens in Mesquite, Texas
02/11/2026
Mesquite's newest urgent care clinic offers accessible, high-quality health care you can count on; Celebrates opening with $5,000 donation to John Horn High School Jaguar Band Key facts of this press release: Integrity [...]
First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT
02/11/2026
100% clinical success and no device-related adverse events in 20 First-in-Human Percutaneous Coronary Intervention procedures with next-generation robotic system Robocath system demonstrates ability to efficiently and [...]
Disc Medicine to Participate in Upcoming Investor Conferences
02/11/2026
WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
02/11/2026
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
02/11/2026
SEATTLE and VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Privia Health Expands VBC Footprint with Acquisition of American Choice Healthcare MSSP Business
02/11/2026
ARLINGTON, Va., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the acquisition of American Choice Healthcare MSSP, LLC (ACH), a wholly-owned subsidiary of Cano Health. The [...]
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
02/11/2026
LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference [...]
Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
02/11/2026
New Findings from Academic Collaboration Examine Tumor-Cell Behavior, TGF-Β/SMAD Signaling & Stromal Responses; Australian Patent Application Filed for the Combination Approach MELBOURNE, Australia, Nov. 02, 2026 ( [...]
TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI’s AVC Solution
02/11/2026
Nanox.AI's Investigational AVC Solution Demonstrated 98.3% Sensitivity and 96.6% Specificity in Evaluable CT Scans . Findings Highlight the Potential of AI to Identify Previously Unreported Aortic Valve Calcification [...]
The Waqf Fund publishes first annual report, marking milestone in charitable investment
02/11/2026
The audited report from one of the UK's largest and fastest growing Waqf funds, details £3.7 million invested in three commercial properties during 2025, with returns set to fund future charitable projects MANCHESTER, [...]
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
02/11/2026
Phase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti- [...]
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
02/11/2026
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug Sustained plasma levels of elraglusib expected to have multiple effects on immune cell dynamics [...]
Radiopharm Theranostics Reports Business Update
02/11/2026
Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration Reported positive Phase 1 [...]
A3P Biomedical appoints Matt Franklin as President, North America to accelerate US market access for Stockholm3
02/11/2026
STOCKHOLM, Nov. 02, 2026 (GLOBE NEWSWIRE) -- A3P Biomedical AB (publ), a Swedish company specializing in advanced prostate cancer screening, today announces the appointment of Matt Franklin as President of A3P [...]
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
02/11/2026
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced [...]
Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
02/11/2026
Predictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if continued Comprehensive analysis and evaluation of available open-label extension data will follow No safety [...]

Pages